

References

**LAXATIVE DRUG PRODUCTS FOR
OVER-THE-COUNTER HUMAN USE;
PROPOSED AMENDMENT TO THE
TENTATIVE FINAL MONOGRAPH**

DOCKET NO. 78N-0368L

(OTC Vol. No. 090TFM6)

REFERENCES:

1. **Adverse Drug Reaction Reports, Ref. 7 in OTC Vol. AF, Docket No. 90N-0200, Division of Dockets Management.**
2. **Comment No. C00100.**
3. **Comment No. LET45.**
4. **Comment No. LET46.**
5. **Adverse Event Reports from 1966 to 2000 for Psyllium Laxative Products (Perdiem, Metamucil, and Serutan) collected by FDA's Office of Compliance, in OTC Vol. 090TFM6.**
6. **FDA, Office of Postmarketing Drug Risk Assessment (OPDRA) (Project ID (PID) 000607) regarding Psyllium Laxative Products Associated with Esophageal Obstruction and Choking, November 17, 2000, in OTC Vol. 090TFM6.**
7. **Adverse Event Reports from January 1999 to January 2001 for Overnight Relief PERDIEM and Fiber Therapy PERDIEM collected by FDA's Office of Compliance in January 2001, in OTC Vol. 090TFM6.**
8. **Adverse Event Reports from October 2000 to January 2002 for Overnight Relief PERDIEM and Fiber Therapy PERDIEM collected by FDA's Office of Compliance in April 2002, in OTC Vol. 090TFM6.**
9. **FDA , Cases of Esophageal Obstruction Associated with PERDIEM (January 1999 to January 2001), in OTC Vol. 090TFM6.**
10. **FDA, OPDRA Postmarketing Safety Review (PID D020201) regarding Senokot and Psyllium Laxative Products Associated with Esophageal Obstruction and Choking, May 15, 2002, in OTC Vol. 090TFM6.**